Clinical Trials Logo

GERD clinical trials

View clinical trials related to GERD.

Filter by:

NCT ID: NCT03574831 Recruiting - GERD Clinical Trials

the Efficency and Safety of Stretta in GERD

Start date: January 2, 2016
Phase:
Study type: Observational

This study evaluated the efficency and safety of the endoscopic radiofrequency procedure(Stretta) in adult gastroesophageal patients.

NCT ID: NCT03568825 Completed - GERD Clinical Trials

Response Surface Pathway Design With Two Interventional- and One Response Variable in Estimating Minimum Efficacy Dose

Start date: September 28, 2016
Phase: N/A
Study type: Interventional

Response Surface Pathway (RSP) design was previously developed for dose-finding studies with one interventional and one response variable, but RSP to higher dimensions is requested. The aim of this study is to introduce and evaluate the RSP design with two interventional and one response variable exemplified by estimating Minimum Efficacy Dose (MED) of Osteopathic Manual Therapy (OMT) in treatment of gastroesophageal reflux disease (GERD).

NCT ID: NCT03561883 Completed - Clinical trials for Gastroesophageal Reflux Disease (GERD)

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Start date: September 6, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard dose PPIs.

NCT ID: NCT03561090 Terminated - Clinical trials for Gastroesophageal Reflux Disease (GERD)

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Start date: June 20, 2018
Phase: Phase 3
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose PPIs.

NCT ID: NCT03558477 Completed - GERD Clinical Trials

PK/PD Clinical Trial of YYD601 in Healthy Adult Male

Start date: September 19, 2017
Phase: Phase 1
Study type: Interventional

A dose block-randomized, open-label, parallel clinical trial

NCT ID: NCT03558425 Completed - GERD Clinical Trials

A Study to Compare PK, PD and Safety of CKD-381 and D026 in Healthy Subjects

Start date: June 27, 2018
Phase: Phase 1
Study type: Interventional

A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy subjects

NCT ID: NCT03536169 Completed - GERD Clinical Trials

Utilization of Anti-reflux Treatment and Course of Illness Leading to Reoperation

Start date: June 1, 2018
Phase:
Study type: Observational

The purpose of this study is to investigate course of illness leading to reoperation after primary anti-reflux surgery and investigate the utilization of anti-reflux treatment, both medical and surgical, in the period 2000-2017

NCT ID: NCT03499171 Recruiting - GERD Clinical Trials

Citalopram for Reflux Hypersensitivity and Functional Heartburn

Start date: May 27, 2019
Phase: Phase 4
Study type: Interventional

Citalopram is a drug used in the treatment of depressive episodes and belongs to the group of selective serotonin reuptake inhibitors (SSRI). Serotonin is an important neurotransmitter predominantly found in the brain and the gastrointestinal tract. Serotonin is associated with psychological disorders, including anxiety and depression, and emotion regulation and it has been shown that anxiety and depression are associated with increased severity of GERD-related symptoms. Citalopram and other SSRI's elevate the concentration of serotonin by blocking the reabsorption into the presynaptic neuron and thereby increasing the level of serotonin available to bind the postsynaptic receptor. A recent study showed beneficial effects of citalopram in patients with reflux hypersensitivity. However, there was no objective measurement for reflux nor esophageal sensitivity during the treatment period. Moreover, the effect of citalopram in patients with functional heartburn has not been studied so far. Therefore, the inevestigators will conduct a randomized, parallel, placebo-controlled study to evaluate the efficacy of citalopram on the improvement in symptom severity, reflux parameters and esophageal sensitivity. 50 patients with reflux hypersensitivity and 50 patients with functional heartburn will receive either placebo or citalopram (Cipramil®) 20 mg as an add-on for a period of 8 weeks. Symptom severity will be assessed by a validated reflux questionnaire (ReQuest questionnaire and diaries), reflux parameters by performing a 24 hour impedance-pH monitoring and esophageal sensitivity using the multimodal esophageal stimulation paradigm

NCT ID: NCT03488147 Withdrawn - Dysphagia Clinical Trials

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

Start date: July 2020
Phase: Phase 2
Study type: Interventional

The researchers wish to investigate whether proton pump inhibitors, administered prior to or after surgery, can reduce the incidence and/or severity of difficulty swallowing foods and/or liquids,following anterior cervical surgery.

NCT ID: NCT03444402 Completed - GERD Clinical Trials

A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects

Start date: March 2, 2018
Phase: Phase 1
Study type: Interventional

A Study to compare pharmacokinetics and safety of CKD-381 and D026 in healthy male subjects